| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2074 | 2017 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1491 | 2018 |
| Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B TT Chang, YF Liaw, SS Wu, E Schiff, KH Han, CL Lai, R Safadi, SS Lee, ... Hepatology 52 (3), 886-893, 2010 | 1250 | 2010 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1044 | 2019 |
| Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC A Melhem, N Muhanna, A Bishara, CE Alvarez, Y Ilan, T Bishara, A Horani, ... Journal of hepatology 45 (1), 60-71, 2006 | 337 | 2006 |
| The fatty acid–bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease R Safadi, FM Konikoff, M Mahamid, S Zelber-Sagi, M Halpern, T Gilat, ... Clinical Gastroenterology and Hepatology 12 (12), 2085-2091. e1, 2014 | 315 | 2014 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 303 | 2022 |
| Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes R Safadi, M Ohta, CE Alvarez, MI Fiel, M Bansal, WZ Mehal, SL Friedman Gastroenterology 127 (3), 870-882, 2004 | 292 | 2004 |
| Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers O Shibolet, Y Ilan, S Gillis, A Hubert, D Shouval, R Safadi Blood, The Journal of the American Society of Hematology 100 (2), 391-396, 2002 | 203 | 2002 |
| NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis C Gur, S Doron, S Kfir-Erenfeld, E Horwitz, L Abu-Tair, R Safadi, ... Gut 61 (6), 885-893, 2012 | 187 | 2012 |
| The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm–volume 2 A Hatzakis, V Chulanov, AC Gadano, C Bergin, Z Ben‐Ari, J Mossong, ... Journal of viral hepatitis 22, 26-45, 2015 | 184 | 2015 |
| Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity E Elinav, G Pinsker, R Safadi, O Pappo, M Bromberg, E Anis, ... Journal of Hepatology 47 (4), 514-520, 2007 | 184 | 2007 |
| Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis N Muhanna, S Doron, O Wald, A Horani, A Eid, O Pappo, SL Friedman, ... Hepatology 48 (3), 963-977, 2008 | 169 | 2008 |
| Amelioration of hepatic fibrosis by NK cell activation N Muhanna, LA Tair, S Doron, J Amer, M Azzeh, M Mahamid, S Friedman, ... Gut 60 (1), 90-98, 2011 | 160 | 2011 |
| Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus O Wald, O Pappo, R Safadi, M Dagan‐Berger, K Beider, H Wald, ... European journal of immunology 34 (4), 1164-1174, 2004 | 158 | 2004 |
| Historical epidemiology of hepatitis C virus (HCV) in select countries–volume 2 V Saraswat, S Norris, RJ De Knegt, JF Sanchez Avila, M Sonderup, ... Journal of viral hepatitis 22, 6-25, 2015 | 142 | 2015 |
| Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression MB Bansal, K Kovalovich, R Gupta, W Li, A Agarwal, B Radbill, ... Journal of hepatology 42 (4), 548-556, 2005 | 141 | 2005 |
| Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial V Ratziu, L De Guevara, R Safadi, F Poordad, F Fuster, J Flores-Figueroa, ... Nature medicine 27 (10), 1825-1835, 2021 | 131 | 2021 |
| Lamivudine treatment for acute severe hepatitis B: a pilot study H Schmilovitz‐Weiss, Z Ben‐Ari, E Sikuler, E Zuckerman, W Sbeit, ... Liver International 24 (6), 547-551, 2004 | 129 | 2004 |
| Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment‐naive patients with HBV‐related decompensated cirrhosis HLY Chan, YC Chen, EJ Gane, SK Sarin, DJ Suh, T Piratvisuth, ... Journal of viral hepatitis 19 (10), 732-743, 2012 | 122 | 2012 |
